Slide 1: Stock exchange filing cover letter
Date: 14 May 2025 To To National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Bandra Kurla Phiroze Jeejeebhoy Towers, Dalal Street Complex, Bandra (E), Mumbai – 400 051 Mumbai – 400001 NSE Scrip Symbol: SaiLife BSE Scrip Code: 544306 Sub: Investor Presentation for the ye
Slide 2: Sai Life Sciences Limited Earnings Presentation
Sai Life Sciences Limited Earnings Presentation May 14, 2025
Slide 3: Safe Harbour
Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "
Slide 4: Message from Managing Director & CEO
Message from Managing Director & CEO “ We are pleased to report a strong performance for FY25, ably supported by solid execution, capacity expansion, and deeper engagement with our customers. Our integrated CRDMO model continues to add value, helping us deliver seamless solutions across the drug dev
Slide 5: Message from Chief Financial Officer
Message from Chief Financial Officer “ We are pleased to report a strong FY25 performance, driven by consistent momentum across our CDMO and CRO segments. Revenue grew by 16% and our EBITDA margin expanded to 25%, in line with our growth aspirations. Profit after tax grew by 105%, supported by lower
Slide 6: Performance Highlights
“ Sai Make it better together Performance Highlights
Slide 7: Robust Yearly Financial Performance
Robust Yearly Financial Performance Revenue (₹ Cr) Material Margin (₹ Cr) and Margin (%) 70% 73% 69% 65% 1,229 1,695 1,019 1,465 1,217 795 603 870 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 EBITDA (₹ Cr) and Margin (%) PAT (₹ Cr) and Margin (%) 25% 425 21% 10% 6% 170 300 15% 15% 1% 1% 182 83 131 6 10 F
Slide 8: Segmental Performance: CDMO & CRO
Segmental Performance: CDMO & CRO CDMO (₹ Cr) 405 321 267 276 257 CDMO CRO 240 148 123 FY25 63% Revenue Q1 Q2 Q3 Q4 37% Contribution CRO (₹ Cr) 164 174 156 135 132 127 117 118 • Both CDMO and CRO businesses continue to demonstrate Q1 Q2 Q3 Q4 growth momentum, supported by increased business from exi
Slide 9: Financial Ratios Overview
Financial Ratios Overview ROCE Gross Fixed Asset Turnover Inventory Days 139 12.3% 85.8% 87.3% 80.1% 115 10.3% 69.0% 93 81 5.1% 3.2% FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 Net Debt/ Equity (x) Net Debt/ EBITDA (x) Net Working Capital Days 5.6 0.84 204 0.80 0.75 3.9 140 122 117 2
Slide 10: Sai Life Sciences Corporate Overview
Sai Life Sciences Corporate Overview
Slide 11: Sai Life Sciences is driven by the eternal teachings of the Saint of Shirdi
Sai Life Sciences is driven by the eternal teachings of the Saint of Shirdi, from whom we derive our name Shraddha - an intense belief or conviction We uphold a sense of Shraddha towards our purpose of using science to accelerate Belief solutions for improving life. Integrity Ownership Respect Our C
Slide 12: We aspire to be the pre-eminent CRDMO partner in Asia-Pacific
We aspire to be the pre-eminent CRDMO partner for global innovators in the Asia-Pacific region Leading Asian CRDMOs grew rapidly during the Sai Life Sciences benchmarks itself with the period from 2018 to 2022, on the back of aggressive best of global players in building its scientific, Capex invest
Slide 13: Corporate Overview
Corporate Overview Two business verticals 4 Global sites; 3000+ Excellence in Discovery and Chemistry, employees Sustainability Manufacturing, & Controls (CMC) 10+ Years 25+ year Enduring customer relationships Focus on track record of delivery Complex Chemistry and new modalities 100% Revenues from
Slide 14: The CRDMO industry is a Service Business with value drivers different from generic pharma
The CRDMO industry is a Service Business with value drivers different from generic pharma companies "As a CRDMO, our value doesn’t hinge on drug approvals—we’re not in the business of binary outcomes. We generate consistent, scalable value through Krishna scientific depth, execution Kanumuri reliabi
Slide 15: Value drivers for CRDMO companies
Value drivers for CRDMO companies • Culture & value system • R&D problem-solving abilities • Ability to scale up novel chemistry at speed • GMP capability and Quality systems • Safety & Sustainability practices • Ability to attract and nurture top talent 14
Slide 16: Typical journey of bringing a new drug to market
Typical journey of bringing a new drug to market Involves screening for potentially active compounds Time frame: 7-12 years that have a therapeutic effect on an intended disease Compounds evaluated: > 10000 Substances identified are refined, optimized, and ex- tensively tested to provide sufficient
Slide 17: Solutions supporting pharmaceutical innovators along the drug discovery journey
Sai Life Sciences has solutions that support pharmaceutical innovators along the entire drug discovery journey Stage 1 Target Validation Early Drug Discovery Sai Life Sciences has to Lead Candidate a play in the monetization Discovery Stage 2 opportunities across the Pre-Clinical Phase Lead Identifi
Slide 18: World-class R&D and Manufacturing facilities in key locations globally
World-class R&D and Manufacturing facilities in key locations globally R&D and manufacturing capacity expansion Process R&D Lab in Alderley underway in India around Global Delivery Model Park | 65 Employees existing sites. Through a strategic mix of onshore and offshore resources, 700 KL GMP Manufac
Slide 19: Discovery Overview
Discovery Overview • Capabilities spanning Target Validation to IND ISO 14001:2015, Certificate of Registration: • 300+ programs successfully delivered ISO 45001:2018 & ISO 50001: Information Security Management 2018 certification System – ISO/IEC 27001:2013 • Integrated services: Medicinal Chemistr
Slide 20: CMC Overview
CMC Overview • End-to-End capabilities from IND through Eco Vadis Silver Medal Signatory of United Nations for Sustainability Global Compact (UNGC) to commercialization • Focus on Complex Chemistry, ADC Payloads & Linkers • Modern, GMP-compliant facilities across UK and India • Flexibility to suppor
Slide 21: Consolidated Statement of Profit and Loss
Consolidated Statement of Profit and Loss Particulars (₹ crores) Q4FY25 Q3FY25 Q4FY24 FY25 FY24 Revenue from operations 580 440 439 1695 1465 Other income 6 4 3 18 14 Total income 586 449 443 1712 1494 Expenses Cost of materials consumed and changes in inventories 168 121 124 466 446 Employee benefi
Slide 22: Thank You
Thank You For more details please contact: Investorrelation@sailife.com © Sai Life Sciences Limited. L4, SLN Terminus, Gachibowli, Hyderabad 500032, Telangana, India.
Slide 23: Glossary
Glossary APIs Active pharmaceutical ingredients Biotechnology companies, often referred to as biotech companies, are largely startups in the pharmaceutical sector which typically focus on developing innovative drugs and drug Biotechs development technologies to address unmet medical needs Blockbuste